Vintage business to grow 12-18% YoY for 5-7 years
Legacy business (exports, institutional, third-party) expected to grow 12-18% annually driven by 1,300-1,400 product registrations.
FREDUNPHARMACEUTICALS / guidance tracker
Keep management guidance in view.
Fredun Pharmaceuticals · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
growth
New-age business to grow 20-25% YoY
Dermatics, pet care, and nutritionals expected to grow 20-25% annually; 51% of revenue by FY29-30.
Further margin expansion in 6-7 quarters
Operating leverage from high-margin new-age brands will drive profit growth over next 6-7 quarters.
No immediate fund requirement for 12-18 months
Current funds and internal cash flows sufficient; no equity raise planned in near term.
FY27 top-line growth of 25-30%
Management expects overall revenue growth of 25-30% in FY27, driven by new-age businesses and steady vintage growth.
PAT margin target of 10-12% in a few years
Management targets PAT margin of 10-12% within the next few years as new-age businesses scale and demographics saturate.
Mobility division to reach ₹100 crore run-rate in 2-2.5 years
Mobility business expected to achieve ₹100 crore run-rate within 2-2.5 calendar years, and ₹250-300 crore in 5-7 years.
Vagger.in platform launch in July 2026
Pet care e-commerce platform Vagger.in to soft-launch in mid-June and full launch in first week of July 2026.